NCT03646591View on ClinicalTrials.gov

Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

August 20, 2018

Study Completion Date

August 20, 2018

Conditions
Chemotherapy Effect
Interventions
DRUG

Chemotherapy

Patients will receive four cycles of the standard dose of FLOT chemotherapy prior to curative gastrectomy. And four cycles of the FLOT chemotherapy is recommended after surgery. Preventive antiemetic and dexamethasone are allowed before chemotherapy, growth factor, or other supportive medicines are allowed for treatment only. Surgical intervention is allowed for acute bleeding or other surgical emergencies.

Trial Locations (1)

200025

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT03646591 - Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China | Biotech Hunter | Biotech Hunter